Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy

Oncology Letters

Volumn 4, Issue 5, 2012, Pages 905-909

  Ono, Tomojiro ^a   Ishida, Hideyuki ^a   Kumamoto, Kensuke ^a   Okada, Norimichi ^a   Ishibashi, Keiichiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Liver metastases; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL EVALUATION; COLON CANCER; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OBSTRUCTIVE JAUNDICE; RECTUM CANCER; TREATMENT OUTCOME;

EID: 84866067714     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.842     Document Type: Article

References (17)

1. Nordlinger B, Sorbye H, Glimelius B, et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016, 2008.
2. Wong R, Cunningham D, Barbachano Y, et al: A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22: 2042-2048, 2011.
3. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671, 2000.
4. National Cancer Institute: Common terminology criteria for adverse events (CTCAE) v4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed April 23, 2012.
5. Benoist S, Brouquet A, Penna C, et al: Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 24: 3939-3945, 2006.
6. Fiorentini G, Del Conte A, De Simone M, et al: Complete response of colorectal liver metastases after intra-arterial chemotherapy. Tumori 94: 489-492, 2008.
7. Elias D, Goere D, Boige V, Kohneh-Sharhi N, Malka D, TomasicG, Dromain C and Ducreux M: Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 14: 3188-3194, 2007.
8. Auer RC, White RR, Kemeny NE, et al: Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 116: 1502-1509, 2010.
9. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, DiazLA and Choti MA: Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 14: 1691-1700, 2010.
10. Tanaka K, Takakura H, Takeda K, Matuo K, Nagano Y and Endo I: Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 250: 935-942, 2009.
11. Klinger M, Epieldauer S, Hacker S, et al: Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35: 515-520, 2009.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
13. Bhattacharjya S, Bhattacharjya T, Baber S, Tibballs JM, Watkinson AF and Davidson BR: Prospective study of contrast-enhanced computed tomography, computed tomography during arterioportography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg 91: 1361-1369, 2004.
14. Bipat S, van Leeuwen MS, Comans EF, et al: Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 237: 123-131, 2005.
15. Vallas C, Andía E, Sánchez A, et al: Hepatic metastases from colorectal cancer: Preoperative detection and assessment of respectability with helical CT. Radiology 218: 55-60, 2001.
16. Elias D, Sideris L, Pocard M, et al: Incidence of unsuspected and treatable metastatic disease associated with operable colorectal liver metastases discovered only at laparotomy (and not treated when performing percutaneous radiofrequency ablation). Ann Surg Oncol 12: 298-302, 2005.
17. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, HawkinsWG and Strasberg SM: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200: 845-853, 2005.